Rho GTPase activating protein 31Genealiases: AOS · AOS1 · CDGAP
Q-omics provides the consensus-scored ARHGAP31 profile across patient tissues and cancer cell-line models. ARHGAP31 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP31 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, ARHGAP31 protein abundance shows 31,586 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where ARHGAP31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP31 survival associations across molecular data types. ARHGAP31 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP31 RNA expression–survival associations across cancer types. High ARHGAP31 expression shows unfavorable associations in MESO and BLCA, but favorable associations in KIRC, HNSC, UVM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGAP31 RNA expression.
This table summarizes ARHGAP31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP31 shows lower tumor expression in LUAD, LUSC, THCA, KIRP and UCEC and higher tumor expression in KIRC. The LUAD box plot shows higher ARHGAP31 RNA expression in normal versus tumor tissue (log2 FC = −2.052, t-test p < 0.001).
This table shows molecular features associated with ARHGAP31 in patient tissues and cancer cell lines. In patient samples, ARHGAP31 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
